Intercept's hotly anticipated NASH drug has to wait for its FDA hearing, thanks to COVID-19

27th March 2020 Uncategorised 0

Intercept Pharmaceuticals and its closely watched nonalcoholic steatohepatitis (NASH) candidate have hit another snag, this one courtesy of the coronavirus pandemic. The FDA has put off an advisory committee review of obeticholic acid, now the lead horse in the hotly contested NASH race.

More: Intercept's hotly anticipated NASH drug has to wait for its FDA hearing, thanks to COVID-19
Source: fierce